Skip to main content
Top
Published in: Journal of Cardiovascular Translational Research 4/2012

Open Access 01-08-2012

Diabetic Complications: Current Challenges and Opportunities

Authors: Helen D. Nickerson, Sanjoy Dutta

Published in: Journal of Cardiovascular Translational Research | Issue 4/2012

Login to get access

Excerpt

The International Diabetes Federation estimates that 366 million people had diabetes in 2011, and that by 2030, this figure will have risen to a staggering 552 million worldwide. In 2011, diabetes was the cause of 4.6 million deaths and accounted for 11 % of adult healthcare expenditure in the USA [1]. The increasing incidence of both type 1 diabetes (T1D) and type 2 diabetes (T2D) elevates the complications of diabetes as one of the most important current public health issues. Complications of diabetes range from acute, life-threatening conditions such as severe hypoglycemia or ketoacidosis to chronic, debilitating complications affecting multiple organ systems, such as retinopathy, nephropathy, neuropathy, and cardiovascular disease. Estimates of the prevalence of diabetic complications are challenging, in part because there are no internationally agreed upon standards for diagnosis. However, a vast majority of those with diabetes will experience one of more of these complications of diabetes. For example, a recent analysis by the META-EYE study group reported that 93 million people worldwide suffer from diabetic retinopathy. For those with 20 or more years of diabetes, three quarters have some form of diabetic retinopathy [2]. …
Literature
1.
go back to reference International Diabetes Federation. (2011). IDF diabetes atlas (5th ed.). Brussels: IDF. International Diabetes Federation. (2011). IDF diabetes atlas (5th ed.). Brussels: IDF.
2.
go back to reference Yau, J. W., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., et al. (2012). Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. doi:10.2337/dc11-1909. Yau, J. W., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., et al. (2012). Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. doi:10.​2337/​dc11-1909.
3.
go back to reference Peterson, L. R., McKenzie, C., Schaffer, J. E. (2012). Diabetic cardiovascular disease: getting to the heart of the matter. Journal of Cardiovascular Translational Research, in press. Peterson, L. R., McKenzie, C., Schaffer, J. E. (2012). Diabetic cardiovascular disease: getting to the heart of the matter. Journal of Cardiovascular Translational Research, in press.
4.
go back to reference Snell-Bergeon, J., & Nadeau, K, (2012). Cardiovascular disease risk in young people with type 1 diabetes. Journal of Cardiovascular Translational Research, in press. Snell-Bergeon, J., & Nadeau, K, (2012). Cardiovascular disease risk in young people with type 1 diabetes. Journal of Cardiovascular Translational Research, in press.
5.
go back to reference Pop-Busui, R. (2012). What do we know and we do not know about cardiovascular autonomic neuropathy in diabetes. Journal of Cardiovascular Translational Research, in press. Pop-Busui, R. (2012). What do we know and we do not know about cardiovascular autonomic neuropathy in diabetes. Journal of Cardiovascular Translational Research, in press.
6.
go back to reference Standards of medical care in diabetes—2012 (2012). Diabetes care. American Diabetes Association, 35(Suppl 1), S11–63. doi: 10.2337/dc12-s011 Standards of medical care in diabetes—2012 (2012). Diabetes care. American Diabetes Association, 35(Suppl 1), S11–63. doi: 10.​2337/​dc12-s011
8.
go back to reference Ruedy, K. J., & Tamborlane, W. V. (2012). The landmark JDRF continuous glucose monitoring randomized trials: a look back at the accumulated evidence. Journal of Cardiovascular Translational Research, in press. Ruedy, K. J., & Tamborlane, W. V. (2012). The landmark JDRF continuous glucose monitoring randomized trials: a look back at the accumulated evidence. Journal of Cardiovascular Translational Research, in press.
11.
go back to reference Kilpatrick, E. S., Rigby, A. S., & Atkin, S. L. (2006). The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care, 29(7), 1486–1490. doi:10.2337/dc06-0293.PubMedCrossRef Kilpatrick, E. S., Rigby, A. S., & Atkin, S. L. (2006). The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care, 29(7), 1486–1490. doi:10.​2337/​dc06-0293.PubMedCrossRef
12.
go back to reference Siegelaar, S. E., Kilpatrick, E. S., Rigby, A. S., Atkin, S. L., Hoekstra, J. B., & Devries, J. H. (2009). Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Diabetologia, 52(10), 2229–2232. doi:10.1007/s00125-009-1473-x.PubMedCrossRef Siegelaar, S. E., Kilpatrick, E. S., Rigby, A. S., Atkin, S. L., Hoekstra, J. B., & Devries, J. H. (2009). Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Diabetologia, 52(10), 2229–2232. doi:10.​1007/​s00125-009-1473-x.PubMedCrossRef
13.
go back to reference Rawlings, R. A., Shi, H., Yuan, L. H., Brehm, W., Pop-Busui, R., & Nelson, P. W. (2011). Translating glucose variability metrics into the clinic via continuous glucose monitoring: a graphical user interface for diabetes evaluation (CGM-GUIDE(c)). Diabetes Technology & Therapeutics, 13(12), 1241–1248. doi:10.1089/dia.2011.0099.CrossRef Rawlings, R. A., Shi, H., Yuan, L. H., Brehm, W., Pop-Busui, R., & Nelson, P. W. (2011). Translating glucose variability metrics into the clinic via continuous glucose monitoring: a graphical user interface for diabetes evaluation (CGM-GUIDE(c)). Diabetes Technology & Therapeutics, 13(12), 1241–1248. doi:10.​1089/​dia.​2011.​0099.CrossRef
14.
go back to reference Marling, C. R., Shubrook, J. H., Vernier, S. J., Wiley, M. T., & Schwartz, F. L. (2011). Characterizing blood glucose variability using new metrics with continuous glucose monitoring data. Journal of Diabetes Science and Technology, 5(4), 871–878.PubMed Marling, C. R., Shubrook, J. H., Vernier, S. J., Wiley, M. T., & Schwartz, F. L. (2011). Characterizing blood glucose variability using new metrics with continuous glucose monitoring data. Journal of Diabetes Science and Technology, 5(4), 871–878.PubMed
15.
go back to reference Clarke, W., & Kovatchev, B. (2009). Statistical tools to analyze continuous glucose monitor data. Diabetes Technology & Therapeutics, 11(Suppl 1), S45–S54. doi:10.1089/dia.2008.0138. Clarke, W., & Kovatchev, B. (2009). Statistical tools to analyze continuous glucose monitor data. Diabetes Technology & Therapeutics, 11(Suppl 1), S45–S54. doi:10.​1089/​dia.​2008.​0138.
17.
go back to reference Paterson, A. D. (2012). Does familial clustering of risk factors for long-term diabetic complications leave any space for genes that do not act through the risk factors? Journal of Cardiovascular Translational Research, in press. Paterson, A. D. (2012). Does familial clustering of risk factors for long-term diabetic complications leave any space for genes that do not act through the risk factors? Journal of Cardiovascular Translational Research, in press.
18.
go back to reference Costacou, T., & Levy, A. P. (2012). Haptoglobin genotype and its role in diabetic cardiovascular disease. Journal of Cardiovascular Translational Research, in press. Costacou, T., & Levy, A. P. (2012). Haptoglobin genotype and its role in diabetic cardiovascular disease. Journal of Cardiovascular Translational Research, in press.
19.
go back to reference Starkey, J. M., & Tilton, R. G. (2012). Understanding the role of proteomics in the systems biology of diabetic nephropathy. Journal of Cardiovascular Translational Research, in press. Starkey, J. M., & Tilton, R. G. (2012). Understanding the role of proteomics in the systems biology of diabetic nephropathy. Journal of Cardiovascular Translational Research, in press.
20.
go back to reference Komorowsky, C. V., Brosius, F. C., Pennathur, S., Kretzler, M. (2012). Perspectives on systems biology applications in diabetic kidney disease. Journal of Cardiovascular Translational Research, in press. Komorowsky, C. V., Brosius, F. C., Pennathur, S., Kretzler, M. (2012). Perspectives on systems biology applications in diabetic kidney disease. Journal of Cardiovascular Translational Research, in press.
21.
go back to reference Calcutt, N. A., Cooper, M. E., Kern, T. S., & Schmidt, A. M. (2009). Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nature Reviews. Drug Discovery, 8(5), 417–429. doi:10.1038/nrd2476.PubMedCrossRef Calcutt, N. A., Cooper, M. E., Kern, T. S., & Schmidt, A. M. (2009). Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nature Reviews. Drug Discovery, 8(5), 417–429. doi:10.​1038/​nrd2476.PubMedCrossRef
22.
go back to reference Sedeek, M., Montezano, A. C., Hebert, R. L., Gray, S. P., Di Marco, E., Jha, J. C., Cooper, M. E., Jandeleit-Dahm, K., Schiffrin, E. L., Wilkinson-Berka, J. L., Touyz, R. M. (2012). Oxidative stress, Nox isoforms and complications of diabetes - potential targets for novel therapies. Journal of Cardiovascular Translational Research. doi: 10.1007/s12265-012-9387-2 Sedeek, M., Montezano, A. C., Hebert, R. L., Gray, S. P., Di Marco, E., Jha, J. C., Cooper, M. E., Jandeleit-Dahm, K., Schiffrin, E. L., Wilkinson-Berka, J. L., Touyz, R. M. (2012). Oxidative stress, Nox isoforms and complications of diabetes - potential targets for novel therapies. Journal of Cardiovascular Translational Research. doi: 10.​1007/​s12265-012-9387-2
23.
go back to reference Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., et al. (2011). Bardoxolone methyl and kidney function in CKD with type 2 diabetes. The New England Journal of Medicine, 365(4), 327–336. doi:10.1056/NEJMoa1105351.PubMedCrossRef Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., et al. (2011). Bardoxolone methyl and kidney function in CKD with type 2 diabetes. The New England Journal of Medicine, 365(4), 327–336. doi:10.​1056/​NEJMoa1105351.PubMedCrossRef
24.
go back to reference Sedeek, M., Callera, G., Montezano, A., Gutsol, A., Heitz, F., Szyndralewiez, C., et al. (2010). Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. American Journal of Physiology. Renal Physiology, 299(6), F1348–F1358. doi:10.1152/ajprenal.00028.2010.PubMedCrossRef Sedeek, M., Callera, G., Montezano, A., Gutsol, A., Heitz, F., Szyndralewiez, C., et al. (2010). Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. American Journal of Physiology. Renal Physiology, 299(6), F1348–F1358. doi:10.​1152/​ajprenal.​00028.​2010.PubMedCrossRef
25.
go back to reference Natarajan, R., Putta, S., Kato, M. (2012). MicroRNAs and diabetic complications. Journal of Cardiovascular Translational Research, in press. Natarajan, R., Putta, S., Kato, M. (2012). MicroRNAs and diabetic complications. Journal of Cardiovascular Translational Research, in press.
26.
go back to reference Keating, S. T., & El-Osta, A. (2012). Chromatin modifications associated with diabetes. Journal of Cardiovascular Translational Research, in press. Keating, S. T., & El-Osta, A. (2012). Chromatin modifications associated with diabetes. Journal of Cardiovascular Translational Research, in press.
27.
go back to reference Prinz, F., Schlange, T., & Asadullah, K. (2011). Believe it or not: how much can we rely on published data on potential drug targets? Nature Reviews. Drug Discovery, 10(9), 712. doi:10.1038/nrd3439-c1.PubMedCrossRef Prinz, F., Schlange, T., & Asadullah, K. (2011). Believe it or not: how much can we rely on published data on potential drug targets? Nature Reviews. Drug Discovery, 10(9), 712. doi:10.​1038/​nrd3439-c1.PubMedCrossRef
29.
go back to reference Wagner, J. A., Wright, E. C., Ennis, M. M., Prince, M., Kochan, J., Nunez, D. J., et al. (2009). Utility of adiponectin as a biomarker predictive of glycemic efficacy is demonstrated by collaborative pooling of data from clinical trials conducted by multiple sponsors. Clinical Pharmacology and Therapeutics, 86(6), 619–625. doi:10.1038/clpt.2009.88.PubMedCrossRef Wagner, J. A., Wright, E. C., Ennis, M. M., Prince, M., Kochan, J., Nunez, D. J., et al. (2009). Utility of adiponectin as a biomarker predictive of glycemic efficacy is demonstrated by collaborative pooling of data from clinical trials conducted by multiple sponsors. Clinical Pharmacology and Therapeutics, 86(6), 619–625. doi:10.​1038/​clpt.​2009.​88.PubMedCrossRef
Metadata
Title
Diabetic Complications: Current Challenges and Opportunities
Authors
Helen D. Nickerson
Sanjoy Dutta
Publication date
01-08-2012
Publisher
Springer US
Published in
Journal of Cardiovascular Translational Research / Issue 4/2012
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI
https://doi.org/10.1007/s12265-012-9388-1

Other articles of this Issue 4/2012

Journal of Cardiovascular Translational Research 4/2012 Go to the issue